Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. (Q37945476)

25 August 2017

Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. (English)

1 reference

25 August 2017

1 reference

1 reference

J Compston

1

1 reference

PubMed ID

21997225

25 August 2017

language of work or name

English

0 references

publication date

14 October 2011

1 reference

Osteoporosis International

25 August 2017

1 reference

25 August 2017

22

1 reference

25 August 2017

12

1 reference

25 August 2017

2951-2961

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-011-1804-x

25 August 2017

0 references

cites work

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Fragility fractures of the hip and femur: incidence and patient characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Effects of non-enzymatic glycation on cancellous bone fragility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Unusual mid-shaft fractures during long-term bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

A physical mechanism for coupling bone resorption and formation in adult human bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate associated osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Potential pathophysiological mechanisms in osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Effect of zoledronate on oral wound healing in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

In vivo effects of zoledronic acid on oral mucosal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Osteonecrosis of the jaw and the role of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Vitamin D and the immune system: new perspectives on an old theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1804-X

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

21 January 2018

1 reference

12 December 2020

Atypical bilateral pedicle fracture in long-term bisphosphonate therapy

1 reference

12 December 2020

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

1 reference

12 December 2020

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

12 December 2020

The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

1 reference

12 December 2020

Surface-associated protein from Staphylococcus aureus stimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology.

1 reference

12 December 2020

Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw

1 reference

12 December 2020

Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia

1 reference

12 December 2020

Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae

1 reference

12 December 2020

Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.

1 reference

12 December 2020

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

12 December 2020

Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone.

1 reference

12 December 2020

The effect of long-term alendronate treatment on cortical thickness of the proximal femur

1 reference

12 December 2020

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer

1 reference

12 December 2020

Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism

1 reference

12 December 2020

Animal models of osteonecrosis of the jaw

1 reference

12 December 2020

Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

1 reference

12 December 2020

Gamma/delta T-cell stimulation by pamidronate

1 reference

12 December 2020

Bacterially induced bone destruction: mechanisms and misconceptions.

1 reference

12 December 2020

Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures

1 reference

12 December 2020

10.1007/S00198-011-1804-X

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21997225